|
[Related PubMed/MEDLINE]
Total Number of Papers: 296
|
|
|
|
|
[Display Entries]
|
|
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
|
Page: of
|
|
|
|
| Abbreviation |
: MZL |
| Long Form |
: marginal zone lymphoma |
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2020 |
A rare face of follicular lymphoma: reverse variant of follicular lymphoma. |
FISH, NLPHL, PTGC, RVFL |
| 2 |
2020 |
Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients. |
ORR |
| 3 |
2020 |
Clonal relationship of marginal zone lymphoma and diffuse large B-cell lymphoma in Sjogren's syndrome patients: case series study and review of the literature. |
DLBCL, IgH, SS |
| 4 |
2020 |
Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models. |
Bcl-2, MCL, MCL1, PI3K |
| 5 |
2020 |
Cost-Effectiveness Analyses, Costs and Resource Use, and Health-Related Quality of Life in Patients with Follicular or Marginal Zone Lymphoma: Systematic Reviews. |
DETs, FL, HRQoL, ICER, NHL, QALY, R-CVP |
| 6 |
2020 |
Epstein-Barr virus-associated large B-cell lymphoma transformation in marginal zone B-cell lymphoma: a series of four cases. |
EBV |
| 7 |
2020 |
Epstein-Barr Virus-negative Marginal Zone Lymphoma as an Uncommon Form of Monomorphic Posttransplant Lymphoproliferative Disorder. |
--- |
| 8 |
2020 |
Extra-Nodal Marginal Zone Lymphoma (MZL) of MALT CD20+ of the Ocular Adnexa: Case Report. |
--- |
| 9 |
2020 |
First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4. |
CR, CR/PR, EFS, FL, FLIPI, iNHLs, LPL, MALT, OS, PFS, PR, RM, SLL, WM |
| 10 |
2020 |
High throughput sequencing reveals high specificity of TNFAIP3 mutations in ocular adnexal marginal zone B-cell lymphomas. |
BL, DLBCL, HTS, OA, PT |
| 11 |
2020 |
Increasing Incidence of B-Cell Non-Hodgkin Lymphoma and Occurrence of Second Primary Malignancies in South Korea: 10-Year Follow-up Using the Korean National Health Information Database. |
B-NHL, CLL/SLL, DLBCL, FL, MCL, NHL, SPM, WM |
| 12 |
2020 |
Integrated analysis of transcriptome, methylome and copy number aberrations data of marginal zone lymphoma and follicular lymphoma in dog. |
DLBCL, FL |
| 13 |
2020 |
Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphoma. |
FCL, PCBCLs |
| 14 |
2020 |
Leptomeningeal metastasis in a marginal zone lymphoma, presenting as a delirium: case report. |
CNS, MBL |
| 15 |
2020 |
Lipid Trait Variants and the Risk of Non-Hodgkin Lymphoma Subtypes: A Mendelian Randomization Study. |
CI, CLL, DLBCL, FL, MR, NHL, OR |
| 16 |
2020 |
Marginal zone lymphoma in a dog. |
--- |
| 17 |
2020 |
Persistent Extranodal Marginal Zone Lymphoma (MZL) in the Capsule of a Re-explanted Silicone Prosthesis Following Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). |
BIA-ALCL |
| 18 |
2020 |
PET/CT in Disease Detection and Follow-up of Subcutaneous Involvement in Marginal Zone Lymphoma. |
PET/CT |
| 19 |
2020 |
Phase II trial evaluating the efficacy and safety of the anti-CD20 monoclonal antibody obinutuzumab in patients with marginal zone lymphoma. |
--- |
| 20 |
2020 |
Primary gastric lymphoma: A report of 16 pediatric cases treated at a single institute and review of the literature. |
H. pylori, MALT, NHLs, PGL |
| 21 |
2020 |
Prognostic Factors in Patients with Low-Grade Nonhodgkin Lymphoma. |
FL, LG-NHL, WM |
| 22 |
2020 |
Prognostic significance of interim PET/CT response for the treatment of advanced-stage marginal zone lymphoma in the post-rituximab era. |
5-PS, FDG, PET/CT, PFS |
| 23 |
2020 |
Radiotherapy of extranodal low-grade follicular and marginal zone lymphomas: long-term follow-up of 159 patients. |
CR, CRR, ENLG, GIT, LC, NHL, ORR, OS, PFS, RT |
| 24 |
2020 |
Single-fraction low-energy electronic brachytherapy for conjunctival lymphoma. |
MALT |
| 25 |
2019 |
An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma. |
CI, FL, LPL/WM, MCL, PFS, Syk |
| 26 |
2019 |
Burden of illness of follicular lymphoma and marginal zone lymphoma. |
FL, NHL |
| 27 |
2019 |
CD13 expression in B cell malignancies is a hallmark of plasmacytic differentiation. |
B-LPD, LPL, WM |
| 28 |
2019 |
Composite breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) and extra-nodal marginal zone lymphoma (MZL) in the capsule of a silicone breast implant. |
BIA-ALCL |
| 29 |
2019 |
Contemporary management of nodal and primary splenic marginal zone lymphoma. |
--- |
| 30 |
2019 |
Cortactin expression in non-Hodgkin B-cell lymphomas: a new marker for the differential diagnosis between chronic lymphocytic leukemia and mantle cell lymphoma. |
CLL, DLBCL, FL, HCL, MCL, SDRPBL |
| 31 |
2019 |
FDG PET/CT as a diagnostic and prognostic tool for the evaluation of marginal zone lymphoma. |
CT, DS, HR, OS, PFS, VAS |
| 32 |
2019 |
Front-line management of indolent non-Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma. |
MCL |
| 33 |
2019 |
Genetically Determined Height and Risk of Non-hodgkin Lymphoma. |
CI, CLL, DLBCL, FL, GWAS, NHL, OR |
| 34 |
2019 |
Immunophenotypic Characterization of Canine Splenic Follicular-Derived B-Cell Lymphoma. |
MCL |
| 35 |
2019 |
Lenalidomide plus rituximab (R2 ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial. |
AE, CR, PR, ORR, PFS |
| 36 |
2019 |
Long Non-Coding RNAs as Molecular Signatures for Canine B-Cell Lymphoma Characterization. |
Bcl, DLBCL, FL, lncRNAs |
| 37 |
2019 |
Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma. |
FL, iNHL, OS, PCR, PFS, SLL |
| 38 |
2019 |
Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network. |
AT, DAAs, DLBCL, HCV, NHL, OS, REL |
| 39 |
2019 |
Lymphoplasmacytic Lymphoma and Marginal Zone Lymphoma. |
LPL |
| 40 |
2019 |
Marginal zone lymphoma-associated antiphospholipid antibodies successfully treated with bendamustine rituximab. |
APLA |
| 41 |
2019 |
Marginal Zone Lymphoma: State-of-the-Art Treatment. |
FL, iNHL, PI3K |
| 42 |
2019 |
Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study. |
CISL, CR, OS, PFS, PR, SD |
| 43 |
2019 |
Refractoriness to rituximab-based therapy and elevated serum B2-microglobulin predict for inferior survival in marginal zone lymphoma. |
B2M, I/ICT |
| 44 |
2019 |
Response to Interferon-Free Direct Antivirals (DAAS) Treatment in Hcv-Related Subcutaneous Marginal Zone B-Cell Lymphoma with Lipoma-Like Presentation: Report of Two Cases. |
DAAS, DAAs, NHL, SVR |
| 45 |
2019 |
Risk for malignancies of infectious etiology among adult survivors of specific non-Hodgkin lymphoma subtypes. |
CI, DLBCL, NHL, SIR |
| 46 |
2019 |
Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ? |
BL, DLBCL, FL, MCL, NHL, PTCL, SEER, SLL |
| 47 |
2019 |
The impact of rheumatological disorders on lymphomas and myeloma: a report on risk and survival from the UK's population-based Haematological Malignancy Research Network. |
ABC, DLBCL |
| 48 |
2019 |
Unclassifiable Isolated Monoclonal Lymphocytosis: Comprehensive Description of a Retrospective Cohort. |
CLL, WHO |
| 49 |
2018 |
A Rare Case of Composite Dural Extranodal Marginal Zone Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. |
CLL, CNS, SLL |
| 50 |
2018 |
Canine Splenic Nodular Lymphoid Lesions: Immunophenotyping, Proliferative Activity, and Clonality Assessment. |
MCL, PARR |
| 51 |
2018 |
Children and adolescents with marginal zone lymphoma have an excellent prognosis with limited chemotherapy or a watch-and-wait strategy after complete resection. |
EMZL, NMZL |
| 52 |
2018 |
Circulating Tfh1 (cTfh1) cell numbers and PD1 expression are elevated in low-grade B-cell non-Hodgkin's lymphoma and cTfh gene expression is perturbed in marginal zone lymphoma. |
cTfh, cTfh1, FL, Tfh, TME |
| 53 |
2018 |
Clinicopathologic characteristics and outcomes of transformed diffuse large B-cell lymphoma in hepatitis C virus-infected patients. |
DLBCL, HCV |
| 54 |
2018 |
Comparison of Myocyte Enhancer Factor 2B Versus Other Germinal Center-associated Antigens in the Differential Diagnosis of B-Cell Non-Hodgkin Lymphomas. |
DLBCL, FL, GC, HGAL, LMO2, MEF2B |
| 55 |
2018 |
Complete metabolic response (CMR) in positron emission tomography-computed tomography (PET-CT) scans may have prognostic significance in patients with marginal zone lymphomas (MZL). |
CMR, PET-CT, PFS |
| 56 |
2018 |
Del17p does not always significantly influence the survival of B-cell chronic lymphoproliferative disorders. |
B-CLPD, CLL, FISH, OS |
| 57 |
2018 |
Effective management strategies for patients with marginal zone lymphoma. |
--- |
| 58 |
2018 |
Evaluation of CD307a expression patterns during normal B-cell maturation and in B-cell malignancies by flow cytometry. |
CLL, MCL |
| 59 |
2018 |
Expanding the Spectrum of EBV-positive Marginal Zone Lymphomas: A Lesion Associated With Diverse Immunodeficiency Settings. |
EBV |
| 60 |
2018 |
High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO. |
ASCT, EFS, NMZL, OS, SMZL |
| 61 |
2018 |
HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. |
CLL/SLL, DLBCL, FL, GWAS, HLA, NHL |
| 62 |
2018 |
Marginal Zone Lymphoma: Clinicopathologic Variations and Approaches to Therapy. |
FDA |
| 63 |
2018 |
Quantitative assessment of informative immunophenotypic markers increases the diagnostic value of immunophenotyping in mature CD5-positive B-cell neoplasms. |
MCL, MFI |
| 64 |
2018 |
Risk Factors for Transformation to Higher-Grade Lymphoma and Its Impact on Survival in a Large Cohort of Patients With Marginal Zone Lymphoma From a Single Institution. |
CR, HGT, IPI, OS, SHR |
| 65 |
2018 |
[Research Progress on Diagnosis and Treatment of B Cell Chronic Lymphoproliferative Disease--Review]. |
B-CLPD, B-PLL, CLL, FL, HCL, LPL/WM, MCL, WHO |
| 66 |
2017 |
A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapy. |
FL, LR-CD, NHL, OS, WM |
| 67 |
2017 |
Chronic amastigote-negative cutaneous leishmaniasis: A clinical, histopathologic and molecular study of 27 cases with emphasis on atypical and pseudolymphomatous presentations. |
CL, PCR |
| 68 |
2017 |
Diffuse Subcutaneous Fat Involvement in a Marginal Zone Lymphoma. |
--- |
| 69 |
2017 |
Dramatic Response with Single-Agent Ibrutinib in Multiply Relapsed Marginal Zone Lymphoma with MYD88L265P Mutation. |
--- |
| 70 |
2017 |
Flow Cytometric Patterns of CD200 and CD1d Expression Distinguish CD10-Negative, CD5-Negative Mature B-Cell Lymphoproliferative Disorders. |
B-LPDs, HCL, HCL-v, LPL |
| 71 |
2017 |
Hepatitis C virus - Associated marginal zone lymphoma. |
DLBCL, HCV |
| 72 |
2017 |
Immunohistochemical analysis of the novel marginal zone B-cell marker IRTA1 in malignant lymphoma. |
GCB, IRTA1 |
| 73 |
2017 |
Long-term outcome of 487 patients with early-stage extra-nodal marginal zone lymphoma. |
--- |
| 74 |
2017 |
Marginal zone lymphoma in elderly and geriatric patients. |
--- |
| 75 |
2017 |
Platelet to lymphocyte ratio (PLR) retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy (R-CVP): Consortium for Improving Survival of Lymphoma trial. |
IPI, PFS, PLR, R-CVP, R-CVP |
| 76 |
2017 |
PRDM1 expression levels in marginal zone lymphoma and lymphoplasmacytic lymphoma. |
LPL |
| 77 |
2017 |
Primary Breast Lymphoma in the United States: 1975-2013. |
ALCL, APC, CI, DLBCL, PBL, SEER |
| 78 |
2017 |
Response assessment with the CXCR4-directed positron emission tomography tracer [68Ga]Pentixafor in a patient with extranodal marginal zone lymphoma of the orbital cavities. |
CNS, MRI, PET |
| 79 |
2017 |
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. |
BCR, CI, ORR |
| 80 |
2017 |
The role of stem-cell transplantation in the treatment of marginal zone lymphoma. |
ASCT |
| 81 |
2017 |
Transformation of marginal zone lymphoma (and association with other lymphomas). |
HT, MALT, NHL |
| 82 |
2017 |
Utility of MYD88 in the Differential Diagnosis and Choice of Second-Line Therapy in a Case of Nonsecretory Lymphoplasmacytic Lymphoma versus Free Light Chain Waldenstrom's Macroglobulinemia. |
LPL, MYD88, NCCN, WM |
| 83 |
2016 |
A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial. |
Ox-P |
| 84 |
2016 |
Amyloid deposition in extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue: A clinicopathologic study of 5 cases. |
MALT |
| 85 |
2016 |
CD180 expression in B-cell lymphomas: A multicenter GEIL study. |
HCL, MdFI |
| 86 |
2016 |
Comprehensive Evaluation of Medical Conditions Associated with Risk of Non-Hodgkin Lymphoma using Medicare Claims ("MedWAS"). |
DLBCL, NHL, SEER, TCL |
| 87 |
2016 |
Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets. |
CLL/SLL, FL, HCL, LPL, MCL, NGS, SBCLs, SMZL |
| 88 |
2016 |
In Situ Hepatitis C NS3 Protein Detection Is Associated with High Grade Features in Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas. |
DLBCL, HCV, NHL, NS3 |
| 89 |
2016 |
Large-scale microarray profiling reveals four stages of immune escape in non-Hodgkin lymphomas. |
DLBCL, FL, GEO, MCL |
| 90 |
2016 |
MALT lymphoma of the left biceps muscle: a rare case with an interesting presentation. |
MALT, NHLs |
| 91 |
2016 |
Marginal zone lymphoma-derived interfollicular diffuse large B-cell lymphoma harboring 20q12 chromosomal deletion and missense mutation of BIRC3 gene: a case report. |
BIRC3, CT, DLBCL, DLBCL-IF, PET |
| 92 |
2016 |
Minimal change disease: an unusual presentation of marginal zone MALT lymphoma. |
MALT, MCD, R-Benda |
| 93 |
2016 |
Primary Marginal Zone Lymphoma in the Posterior Mediastinum with Pleural Involvement. |
--- |
| 94 |
2016 |
Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. |
CI, MR, ORR, RESORT, RR, SLL, TTTF |
| 95 |
2016 |
The genetic landscape of dural marginal zone lymphomas. |
LOH |
| 96 |
2016 |
[A Case of Primary Dural Lymphoma of Jugular Tubercle Mimicking Lower Clival Meningioma]. |
CT, MRI, PCNSL, PDL |
| 97 |
2016 |
[Marginal zone lymphoma with monoclonal immunoglobulin: three cases report and literatures review]. |
CR, MALTL, mc Ig, ORR |
| 98 |
2015 |
A genome-wide association study of marginal zone lymphoma shows association to the HLA region. |
--- |
| 99 |
2015 |
Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study. |
AT, B-NHL, DLBCL, HCV, OS |
| 100 |
2015 |
EBV-related primary splenic lymphocyte-depleted classical Hodgkin lymphoma. |
cHL, LDCHL |
|
A Search Service for Abbreviation / Long Form
